Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Oncologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
July 21, 2008
As if Rituxan (Genentech/Biogen) needed another market?
Analysis of: Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation | content.nejm.org
Author: GLG Expert Contributor
For patients with antibodies that may make renal transplants problematic, Rituxan may make them possible!
July 14, 2008
Notice the US is not part of the discussion?
Analysis of: Glaxo Seeks Guidance From Health Systems | online.wsj.com
Author: GLG Expert Contributor
GSK is discussing drug development with European countries and not the US. Implications???
July 10, 2008
Medicare fee cuts: Saved by someone who may appreciate the significance........
Analysis of: Bill to Block Medicare-Fee Cuts | online.wsj.com
Author: GLG Expert Contributor
Medicare will not cut physicians fees but will cut payments in HMO driven Medicare "advantage" plans. This means that the republicans will be unable to "feather the nest" of their insurer friends!
July 9, 2008
This is not new news about Avastin
Analysis of: Costly Cancer Drug Offers Hope, but Also a Dilemma | www.nytimes.com
Author: GLG Expert Contributor
Avastin is only one of many new targeted therapies that are expensive.  It was first introduced in colon cancer and has helped to extend the survival of metastatic colon cancer from 3-6 months to 2 years. It has recently been approved for use in lung and breast cancers as well.  It is in these...
July 9, 2008
Further evidence that government intervention is around the corner
Analysis of: Pricey Drugs Put Squeeze on Doctors | online.wsj.com
Author: GLG Expert Contributor
Chemotherapy drugs are so costly that not only are the patients unable to pay co-pays, but oncologists are laying out hundreds of thousands of dollars with only a promise they will be reimbursed.
July 8, 2008
What ever happens I can assure you the Doctors will be f........
Analysis of: Clash on Preventing Cut to Doctor Payments | online.wsj.com
Author: GLG Expert Contributor
11% drop in physician re-imbursement vs HMO sponsored Medicare "advantage" programs. Who will win out?
July 7, 2008
Cost vs Efficacy: A conundrum for insurers, physicians and patients.
Analysis of: Costly Cancer Drug Offers Hope, but Also a Dilemma | www.nytimes.com
Author: GLG Expert Contributor
Extraordinarily expensive Avastin makes all think twice before using, due to ?? efficacy data as well as questions re: quality of life v survival benefits.
July 7, 2008
One Drug Many Uses: Prove It
Analysis of: One drug, many uses. Good idea? | www.indystar.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Lilly has devoted substantial energy/expense in developing Cymbalta for many indications.  Is this at the expense of developing novel agents? 
July 7, 2008
Can China Make Generics Better than They Make Toys
Analysis of: China Muscles In On The Generics Industry | www.pharmalot.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Several Chinese companies are set to enter the generic drug market ove the next year.  If these agents are demonstrated to be safe, they could have a large impact on the generic drug industry.
July 7, 2008
Avastin Effecitve in Lung and Breast Cancer But is it Cost Effective?
Analysis of: Roche decision denies cancer drug to Britons | www.ft.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Roche has elected not to provide information on the cost effectiveness and clinical effectiveness of Avastin in breast cancer to the medicine advisory board of the British government.  As such, the drug will not be able for first line treatment of these diseases in Britain.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next81 to 90 of 1055

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-04T21:45:18.380